Plenty of run left in Genetic Signatures
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Less than a fortnight ago Finfeed noted Genetic Signature Ltd’s (ASX: GSS) news that it had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-2), the virus that causes COVID-19.
Management also noted at the time that it had submitted a formal application for European CE-IVD registration for a new real-time PCR (polymerase chain reaction).
I saw these developments as particularly significant for the company, and indeed shares in the company surged on the day the news was released.
There has been continual strong news flow from the company, as it received CE-IVD registration for its SARS-CoV-2 Detection Kit, as well as notification from the Therapeutic Goods Administration (TGA) that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to be listed on the ARTG in Australia.
Not surprisingly, this has provided significant share price momentum, and since the company first came under Finfeed’s spotlight its shares have increased from $1.10 to $2.08.
Bell Potter sees upside of 25%
Bell Potter analyst Tanushree Jain likes the story, and just last week he upgraded his price target from $1.50 to $2.60 saying, ‘’March quarter 2020 revenue of $1.8 million (up 71% year-on-year), set a new record for GSS.
‘’The increase was driven by initial sales of GSS’ COVID-19 testing kit in Australia and the European Union (under regulatory exemptions).
‘’Formal regulatory approvals in the European Union and Australia for the kit were received in April.
‘’All indications are that the three months to June 30, 2020 will be another record quarter (Bell Potter estimates revenues of $5 million), with indicative revenue for Apr’20 alone at $1.7 million.’’
Consequently, while the company’s shares have had a strong run, Hester still sees upside of 25% relative to Friday’s closing price of $2.08.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.